(R)-3-(4-(6-Amino-5-formylpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

Catalog No. :
ACQNGH948
CAS No. :
2606144-45-8
Molecular Formula :
C16H18N6O
Molecular Weight :
310.36

IUPAC Name:(R)-3-(4-(6-amino-5-formylpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

(R)-3-(4-(6-Amino-5-formylpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-3-(4-(6-Amino-5-formylpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
IUPAC Name(R)-3-(4-(6-amino-5-formylpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Molecular FormulaC16H18N6O
Molecular Weight310.36
SMILESO=CC1=C(C2=CN([C@H](CC#N)C3CCCC3)N=C2)N=CN=C1N
InChI KeyMHFAFIWXZXNGJT-CQSZACIVSA-N
Synonym1H-Pyrazole-1-propanenitrile, 4-(6-amino-5-formyl-4-pyrimidinyl)-β-cyclopentyl-, (βR)-;(R)-3-(4-(6-Amino-5-formylpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;3-(4-(6-amino-5-formylpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;*Amphetamine Impurity 3 (Amphetamine EP Impurity C);Lucotinib Impurity 4;Ruxolitinib Impurity 2 p-Toluenesulfonate;Ruxolitinib Impurity 03;Lucitinib Impurity 15
CAS No.2606144-45-8

Synthetic Route by SureRoute

1. ACQNGH948 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFHMI091 route compound structure diagram
    ACFHMI0911146629-84-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACQNGH948 route product structure diagram
    ACQNGH9482606144-45-8
Inquiry

2. ACQNGH948 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQNGH948 route product structure diagram
    ACQNGH9482606144-45-8
Inquiry

Comments (0)